Drugs / Trichomylin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04867057 | Apr 2021 → Feb 2022 | osteoarthritis | ZYUS Life Sciences Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06533657 | Jun 2025 → Apr 2026 | — | ZYUS Life Sciences Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-01-08 | ZYUS Life Sciences Inc. | Results ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug zyus.com ↗
today announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain. |
| 2024-07-30 | ZYUS Life Sciences Inc. | Regulatory ZYUS Life Sciences Receives No Objection Letter from Health Canada for Proof-of-Concept Trial zyus.com ↗
The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. |
| 2024-04-23 | ZYUS Life Sciences Inc. | Regulatory ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management zyus.com ↗ |
| 2023-11-21 | ZYUS Life Sciences Inc. | Results ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels zyus.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trichomylin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06533657 ↗ |
| Route | Oral | “will be administered orally as a single dose.” NCT04867057 ↗ |